In Memoriam: Rachna Shroff, MD, MS, FASCO: A Life Dedicated to Advancing Cancer Care
RYZ101 Improves PFS in Phase 3 ACTION-1 Trial for GEP-NETs After Lutetium-177 Therapy
Advanced Bladder Cancer: How Is First-Line Treatment Changing?
Unresectable Stage III NSCLC: PACIFIC Remains the Backbone as Precision Strategies Reshape Care
NRG-BR002: Metastasis-Directed Ablation Fails to Improve PFS or OS in Oligometastatic Breast Cancer
Merck at ESMO 2026: Phase 3 mRNA, TROP2 ADC and Pembrolizumab Data Lead 90+ Abstracts
IARC Director Elisabete Weiderpass to Discuss How to Turn Cancer Research Into Action at Momentum 2026
Secure Your Place at the European Cancer Summit and Help Shape the Future of Cancer Research - ECO
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
